)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
Our latest articles
)
In Handelsblatt's new HR guide “Future of Work,” Oliver Kremer, founder and CEO of K-Recruiting, shares his perspective on the future of work. He shows why freelancers are not a risk but an opportunity for companies and how hybrid teams are becoming the model for success in the modern working world.
)
This time, the focus was on enthusiasm, customer-centricity, and leadership. Guests from the Life Sciences industry experienced in Paul Johannes Baumgartner’s keynote how Positive Leadership and emotionally engaging customer experiences can turn clients into true fans. This energy carried over into personal interactions, sparking many inspiring conversations.
)
In the F.A.Z., Oliver Kremer, Founder and CEO of K-Recruiting, commented on the effects of demographic change on the labor market. In particular, the importance of freelancers and flexible working models, which K-Recruiting has been establishing since 2014, was discussed. Find out more in the article.
)
At the 6th Connecting Day, decision-makers from the life sciences industry and top freelancers came together to exchange ideas on AI and the future of work. Highlight: an inspiring keynote by Microsoft’s Anna Kopp - rounded off by networking in a relaxed atmosphere.
)
Our 5th Connecting Day on November 20 successfully rounded off our event series for 2024. The event not only offered valuable networking opportunities, but also provided inspiring insights into the importance of team spirit for achieving personal and shared goals.
)
The discovery of the importance of miRNA, which was awarded with this year's Nobel Prize in Medicine and Physiology, marked a milestone and opened up new possibilities for personalized therapies. These tiny molecules regulate genetic processes and offer great potential in the treatment of serious diseases. But how close are we to a medical revolution - and what challenges remain?
)
mRNA cancer vaccines could revolutionize cancer treatment by specifically mobilizing the immune system against tumors. BioNTech is testing personalized vaccines in the UK, while Moderna presented promising results with a skin cancer vaccine at the ASCO congress. Despite the progress made, researchers still face challenges such as high costs and extensive studies.
)
The Clinical Trials Information System (CTIS) marks a significant step forward in the management of clinical trials in the EU. The harmonization and digitalization of the process offer enormous advantages for all parties involved. With the deadline of January 31, 2025 approaching, the urgency to switch to CTIS is now tangible and requires immediate action.
)
)
Our 4th Connecting Day on 07.05.2024 marked another milestone in our event series. In addition to an impressive lecture by SPIEGEL bestselling author Prof. Dr. Volker Busch, the participants enjoyed the relaxed networking atmosphere above the rooftops of Munich.